Bridgestone celebrates 30 year Leukaemia Foundation partnership with three-year commitment
Publish Date: 22/7/2016
Celebrating 30 years of partnership between Bridgestone and the Leukaemia Foundation at a black tie ‘Iridescence’ gala ball, Bridgestone announced a new three year commitment to continue its vital support of the Leukaemia Foundation.
The Bridgestone and Leukaemia Foundation’s ‘Iridescence” gala ball attracted more than 370 people to the Adelaide Convention Centre in June and raised more than $85,000 to fund research into better treatments for leukaemia, lymphoma, myeloma and related blood disorders.
“Unlike some other diseases, blood cancer does not discriminate between men, women and children – it can affect anyone at any time of their life,” said Bridgestone Australia and New Zealand Managing Director Andrew Moffatt.
“We made the decision a long time ago that we wanted to direct our energies to a cause that affects many lives and with whom we could make a real, long-term difference.
“It began in 1986 with the provision of the first transport vehicle and has grown since then. It’s now part of our DNA and a critical part of our planning every year.
“Iridescence was a celebration of what we have achieved together. However, we remain committed to helping the Foundation wherever we can and we’re incredibly excited about the new partnership agreement and what it will enable us to achieve over the coming three years.”
Bridgestone’s support of the Leukaemia Foundation includes:
- Principal Partner of Light the Night;
- Principal Partner of the Aussie Muscle Car Run;
- Bridgestone’s blue valve cap campaign, which funds the Leukaemia Foundation’s Career Grant (valued at $50,000); and
- Sponsorship of 10 transport vehicles across the country.
The flagship of this support is the Bridgestone Australia Leukaemia Foundation Village in Lightsview, which provides regional families with a home-away-from-home while they undergo treatment in Adelaide.
“So much has been achieved over an incredible three decades to help families affected by blood cancer,” said Simon Matthias, Leukaemia Foundation General Manager SA/NT.
“Not only did ‘Iridescence’ recognise all the work that has been done so far, it has also highlighted the need for us to continue working together to ensure that the 13,000 Australians diagnosed with blood cancer each year can achieve a better quality of life during their treatment and, most importantly, have hope for their long term recovery.
“Bridgestone’s support of the Leukaemia Foundation is vital and we are extremely grateful for the new three-year commitment to help us in our quest for a blood cancer free future.”